Bridgeway Capital Management, LLC Cel Sci Corp Transaction History

Bridgeway Capital Management, LLC

$4.24 Billion
Q4 2024

A detailed history of Bridgeway Capital Management, LLC transactions in Cel Sci Corp stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 114,300 shares of CVM stock, worth $48,006. This represents 0.0% of its overall portfolio holdings.

Number of Shares

114,300

Previous 118,300 3.38%

Holding current value

$48,006

Previous $125,000 64.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.4 - $1.11 $1,600 - $4,440	-4,000 Reduced 3.38%	114,300 $45,000
Q2 2024 Aug 14, 2024	SELL	$1.11 - $1.85 $37,296 - $62,160	-33,600 Reduced 22.12%	118,300 $137,000
Q1 2024 May 15, 2024	BUY	$1.63 - $3.08 $3,260 - $6,160	2,000 Added 1.33%	151,900 $290,000
Q3 2023 Nov 14, 2023	BUY	$1.17 - $2.86 $70,200 - $171,600	60,000 Added 66.74%	149,900 $187,000
Q2 2023 Aug 14, 2023	SELL	$2.11 - $2.83 $73,850 - $99,050	-35,000 Reduced 28.02%	89,900 $216,000
Q4 2022 Feb 14, 2023	BUY	$1.99 - $3.52 $52,934 - $93,632	26,600 Added 27.06%	124,900 $293,000
Q3 2022 Nov 14, 2022	BUY	$3.09 - $5.23 $303,747 - $514,109	98,300 New	98,300 $304,000
Q1 2020 May 15, 2020	SELL	$7.54 - $17.05 $1.04 Million - $2.34 Million	-137,300 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.0 - $9.6 $150,000 - $240,000	-25,000 Reduced 15.4%	137,300 $1.23 Million
Q1 2019 May 15, 2019	BUY	$2.58 - $3.54 $315,534 - $432,942	122,300 Added 305.75%	162,300 $575,000
Q1 2018 May 15, 2018	BUY	$1.38 - $2.33 $55,199 - $93,200	40,000 New	40,000 $56,000

Others Institutions Holding CVM

# of Institutions

Shares Held

6.95M

Call Options Held

38.3K

Put Options Held

184K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $18.2M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.

Account

Bridgeway Capital Management, LLC Cel Sci Corp Transaction History